array(40) {
  [0]=>
  string(4) "2990"
  ["article_id"]=>
  string(4) "2990"
  [1]=>
  string(76) "EC approves ZYNTEGLO gene therapy for transfusion-dependent β-thalassemia"
  ["article_title"]=>
  string(76) "EC approves ZYNTEGLO gene therapy for transfusion-dependent β-thalassemia"
  [2]=>
  string(157) "The approval for ZYNTEGLO is for the treatment of TDT in patients 12 years and older who do not have a β0/β0 genotype and for those who are &#nlThe pos"
  ["short_description"]=>
  string(157) "The approval for ZYNTEGLO is for the treatment of TDT in patients 12 years and older who do not have a β0/β0 genotype and for those who are &#nlThe pos"
  [3]=>
  string(518) "
The approval for ZYNTEGLO is for the treatment of TDT in patients 12 years and older who do not have a β0/β0 genotype and for those who are 
&#nl
The post EC approves ZYNTEGLO gene therapy for transfusion-dependent β-thalassemia appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(518) "
The approval for ZYNTEGLO is for the treatment of TDT in patients 12 years and older who do not have a β0/β0 genotype and for those who are 
&#nl
The post EC approves ZYNTEGLO gene therapy for transfusion-dependent β-thalassemia appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(77) "https://www.pharmaceutical-business-review.com/news/ec-approves-zynteglo-ttd/"
  ["blog_url"]=>
  string(77) "https://www.pharmaceutical-business-review.com/news/ec-approves-zynteglo-ttd/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-06-09 21:57:40"
  ["create_at"]=>
  string(19) "2019-06-09 21:57:40"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "2989"
  ["article_id"]=>
  string(4) "2989"
  [1]=>
  string(70) "Eli Lilly gets FDA nod for Emgality to treat episodic cluster headache"
  ["article_title"]=>
  string(70) "Eli Lilly gets FDA nod for Emgality to treat episodic cluster headache"
  [2]=>
  string(150) "Emgality, which is an advanced therapeutic approach for the neurologic disease, is claimed to be the first and only calcitonin gene-related peptide (C"
  ["short_description"]=>
  string(150) "Emgality, which is an advanced therapeutic approach for the neurologic disease, is claimed to be the first and only calcitonin gene-related peptide (C"
  [3]=>
  string(553) "
Emgality, which is an advanced therapeutic approach for the neurologic disease, is claimed to be the first and only calcitonin gene-related peptide (CGRP) antibody approved by the FDA 
&#nl
The post Eli Lilly gets FDA nod for Emgality to treat episodic cluster headache appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(553) "
Emgality, which is an advanced therapeutic approach for the neurologic disease, is claimed to be the first and only calcitonin gene-related peptide (CGRP) antibody approved by the FDA 
&#nl
The post Eli Lilly gets FDA nod for Emgality to treat episodic cluster headache appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(80) "https://www.pharmaceutical-business-review.com/news/eli-lilly-emgality-headache/"
  ["blog_url"]=>
  string(80) "https://www.pharmaceutical-business-review.com/news/eli-lilly-emgality-headache/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-06-09 21:57:40"
  ["create_at"]=>
  string(19) "2019-06-09 21:57:40"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "2988"
  ["article_id"]=>
  string(4) "2988"
  [1]=>
  string(88) "Reata Pharmaceuticals gets orphan drug designation for bardoxolone methyl to treat ADPKD"
  ["article_title"]=>
  string(88) "Reata Pharmaceuticals gets orphan drug designation for bardoxolone methyl to treat ADPKD"
  [2]=>
  string(152) "ADPKD is the most common inherited form of kidney disease affecting approximately 140,000 patients in the United States.  It is characterized by the "
  ["short_description"]=>
  string(152) "ADPKD is the most common inherited form of kidney disease affecting approximately 140,000 patients in the United States.  It is characterized by the "
  [3]=>
  string(645) "
ADPKD is the most common inherited form of kidney disease affecting approximately 140,000 patients in the United States.  It is characterized by the development of pathologic fluid-filled cysts 
&#nl
The post Reata Pharmaceuticals gets orphan drug designation for bardoxolone methyl to treat ADPKD appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(645) "
ADPKD is the most common inherited form of kidney disease affecting approximately 140,000 patients in the United States.  It is characterized by the development of pathologic fluid-filled cysts 
&#nl
The post Reata Pharmaceuticals gets orphan drug designation for bardoxolone methyl to treat ADPKD appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(141) "https://www.pharmaceutical-business-review.com/news/reata-pharmaceuticals-gets-orphan-drug-designation-for-bardoxolone-methyl-to-treat-adpkd/"
  ["blog_url"]=>
  string(141) "https://www.pharmaceutical-business-review.com/news/reata-pharmaceuticals-gets-orphan-drug-designation-for-bardoxolone-methyl-to-treat-adpkd/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-06-09 21:57:40"
  ["create_at"]=>
  string(19) "2019-06-09 21:57:40"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "2987"
  ["article_id"]=>
  string(4) "2987"
  [1]=>
  string(84) "CStone secures approval in China for clinical trial of CS1001, BLU-554 combo for HCC"
  ["article_title"]=>
  string(84) "CStone secures approval in China for clinical trial of CS1001, BLU-554 combo for HCC"
  [2]=>
  string(150) "The trial is a multi-center, open-label, and multi-dose Phase Ib/II study that aims to evaluate the safety, tolerability, pharmacokinetics, pharmacody"
  ["short_description"]=>
  string(150) "The trial is a multi-center, open-label, and multi-dose Phase Ib/II study that aims to evaluate the safety, tolerability, pharmacokinetics, pharmacody"
  [3]=>
  string(652) "
The trial is a multi-center, open-label, and multi-dose Phase Ib/II study that aims to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor efficacy of the combination in advanced 
&#nl
The post CStone secures approval in China for clinical trial of CS1001, BLU-554 combo for HCC appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(652) "
The trial is a multi-center, open-label, and multi-dose Phase Ib/II study that aims to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor efficacy of the combination in advanced 
&#nl
The post CStone secures approval in China for clinical trial of CS1001, BLU-554 combo for HCC appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(136) "https://www.pharmaceutical-business-review.com/news/cstone-secures-approval-in-china-for-clinical-trial-of-cs1001-blu-554-combo-for-hcc/"
  ["blog_url"]=>
  string(136) "https://www.pharmaceutical-business-review.com/news/cstone-secures-approval-in-china-for-clinical-trial-of-cs1001-blu-554-combo-for-hcc/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-06-09 21:57:40"
  ["create_at"]=>
  string(19) "2019-06-09 21:57:40"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "2986"
  ["article_id"]=>
  string(4) "2986"
  [1]=>
  string(70) "Venetoclax, obinutuzumab combo meets objective in phase 3 trial in CLL"
  ["article_title"]=>
  string(70) "Venetoclax, obinutuzumab combo meets objective in phase 3 trial in CLL"
  [2]=>
  string(150) "The venetoclax, obinutuzumab combination met the primary endpoint of the late-stage trial called CLL14, which was investigator-assessed progression-fr"
  ["short_description"]=>
  string(150) "The venetoclax, obinutuzumab combination met the primary endpoint of the late-stage trial called CLL14, which was investigator-assessed progression-fr"
  [3]=>
  string(600) "
The venetoclax, obinutuzumab combination met the primary endpoint of the late-stage trial called CLL14, which was investigator-assessed progression-free survival (PFS). The combination therapy, which was administered for a 
&#nl
The post Venetoclax, obinutuzumab combo meets objective in phase 3 trial in CLL appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(600) "
The venetoclax, obinutuzumab combination met the primary endpoint of the late-stage trial called CLL14, which was investigator-assessed progression-free survival (PFS). The combination therapy, which was administered for a 
&#nl
The post Venetoclax, obinutuzumab combo meets objective in phase 3 trial in CLL appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(88) "https://www.pharmaceutical-business-review.com/news/venetoclax-obinutuzumab-cll-phase-3/"
  ["blog_url"]=>
  string(88) "https://www.pharmaceutical-business-review.com/news/venetoclax-obinutuzumab-cll-phase-3/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-06-09 21:57:40"
  ["create_at"]=>
  string(19) "2019-06-09 21:57:40"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "2985"
  ["article_id"]=>
  string(4) "2985"
  [1]=>
  string(76) "Goldfinch Bio initiates phase 1 clinical trial of GFB-887 for kidney disease"
  ["article_title"]=>
  string(76) "Goldfinch Bio initiates phase 1 clinical trial of GFB-887 for kidney disease"
  [2]=>
  string(150) "The Phase 1 study will evaluate the safety, tolerability, and pharmacokinetic profile of GFB-887 in healthy volunteers and in patients with chronic ki"
  ["short_description"]=>
  string(150) "The Phase 1 study will evaluate the safety, tolerability, and pharmacokinetic profile of GFB-887 in healthy volunteers and in patients with chronic ki"
  [3]=>
  string(613) "
The Phase 1 study will evaluate the safety, tolerability, and pharmacokinetic profile of GFB-887 in healthy volunteers and in patients with chronic kidney disease. Topline safety data from 
&#nl
The post Goldfinch Bio initiates phase 1 clinical trial of GFB-887 for kidney disease appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(613) "
The Phase 1 study will evaluate the safety, tolerability, and pharmacokinetic profile of GFB-887 in healthy volunteers and in patients with chronic kidney disease. Topline safety data from 
&#nl
The post Goldfinch Bio initiates phase 1 clinical trial of GFB-887 for kidney disease appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(129) "https://www.pharmaceutical-business-review.com/news/goldfinch-bio-initiates-phase-1-clinical-trial-of-gfb-887-for-kidney-disease/"
  ["blog_url"]=>
  string(129) "https://www.pharmaceutical-business-review.com/news/goldfinch-bio-initiates-phase-1-clinical-trial-of-gfb-887-for-kidney-disease/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-06-09 21:57:40"
  ["create_at"]=>
  string(19) "2019-06-09 21:57:40"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "2984"
  ["article_id"]=>
  string(4) "2984"
  [1]=>
  string(58) "Vertex Pharmaceuticals to buy US firm Exonics Therapeutics"
  ["article_title"]=>
  string(58) "Vertex Pharmaceuticals to buy US firm Exonics Therapeutics"
  [2]=>
  string(152) "Under the deal, Exonics equity holders will receive $245m (£192m) upfront payment from Vertex, as well as potential future payments based on the achi"
  ["short_description"]=>
  string(152) "Under the deal, Exonics equity holders will receive $245m (£192m) upfront payment from Vertex, as well as potential future payments based on the achi"
  [3]=>
  string(546) "
Under the deal, Exonics equity holders will receive $245m (£192m) upfront payment from Vertex, as well as potential future payments based on the achievement of specified development and 
&#nl
The post Vertex Pharmaceuticals to buy US firm Exonics Therapeutics appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(546) "
Under the deal, Exonics equity holders will receive $245m (£192m) upfront payment from Vertex, as well as potential future payments based on the achievement of specified development and 
&#nl
The post Vertex Pharmaceuticals to buy US firm Exonics Therapeutics appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(80) "https://www.pharmaceutical-business-review.com/news/vertex-exonics-therapeutics/"
  ["blog_url"]=>
  string(80) "https://www.pharmaceutical-business-review.com/news/vertex-exonics-therapeutics/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-06-09 21:57:40"
  ["create_at"]=>
  string(19) "2019-06-09 21:57:40"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "2983"
  ["article_id"]=>
  string(4) "2983"
  [1]=>
  string(70) "Novartis says iscalimab may prolong durability of transplanted kidneys"
  ["article_title"]=>
  string(70) "Novartis says iscalimab may prolong durability of transplanted kidneys"
  [2]=>
  string(150) "“Extending the life of transplanted kidneys would mean fewer patients going back on dialysis or needing a second transplant – relieving pr"
  ["short_description"]=>
  string(150) "“Extending the life of transplanted kidneys would mean fewer patients going back on dialysis or needing a second transplant – relieving pr"
  [3]=>
  string(593) "
“Extending the life of transplanted kidneys would mean fewer patients going back on dialysis or needing a second transplant – relieving pressure on waiting lists that in the 
&#nl
The post Novartis says iscalimab may prolong durability of transplanted kidneys appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(593) "
“Extending the life of transplanted kidneys would mean fewer patients going back on dialysis or needing a second transplant – relieving pressure on waiting lists that in the 
&#nl
The post Novartis says iscalimab may prolong durability of transplanted kidneys appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(118) "https://www.pharmaceutical-business-review.com/news/novartis-presents-first-of-its-kind-histology-data-with-iscalimab/"
  ["blog_url"]=>
  string(118) "https://www.pharmaceutical-business-review.com/news/novartis-presents-first-of-its-kind-histology-data-with-iscalimab/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-06-09 21:57:40"
  ["create_at"]=>
  string(19) "2019-06-09 21:57:40"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "2982"
  ["article_id"]=>
  string(4) "2982"
  [1]=>
  string(73) "Calquence, obinutuzumab combo meets primary endpoint in phase 3 CLL trial"
  ["article_title"]=>
  string(73) "Calquence, obinutuzumab combo meets primary endpoint in phase 3 CLL trial"
  [2]=>
  string(150) "The Calquence, obinutuzumab combination registered a statistically-significant and clinically-meaningful improvement in progression-free survival (PFS"
  ["short_description"]=>
  string(150) "The Calquence, obinutuzumab combination registered a statistically-significant and clinically-meaningful improvement in progression-free survival (PFS"
  [3]=>
  string(604) "
The Calquence, obinutuzumab combination registered a statistically-significant and clinically-meaningful improvement in progression-free survival (PFS) during the trial, which was the primary endpoint. This was in comparison to the 
&#nl
The post Calquence, obinutuzumab combo meets primary endpoint in phase 3 CLL trial appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(604) "
The Calquence, obinutuzumab combination registered a statistically-significant and clinically-meaningful improvement in progression-free survival (PFS) during the trial, which was the primary endpoint. This was in comparison to the 
&#nl
The post Calquence, obinutuzumab combo meets primary endpoint in phase 3 CLL trial appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(80) "https://www.pharmaceutical-business-review.com/news/calquence-phase-3-cll-trial/"
  ["blog_url"]=>
  string(80) "https://www.pharmaceutical-business-review.com/news/calquence-phase-3-cll-trial/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-06-09 21:57:40"
  ["create_at"]=>
  string(19) "2019-06-09 21:57:40"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "2766"
  ["article_id"]=>
  string(4) "2766"
  [1]=>
  string(94) "Professor Green and Andrew Flintoff address the key issues with mental health in the workplace"
  ["article_title"]=>
  string(94) "Professor Green and Andrew Flintoff address the key issues with mental health in the workplace"
  [2]=>
  string(150) "Mental health issues can affect anybody, regardless of their age, personality or workplace – and that includes the rich and famous. British rapp"
  ["short_description"]=>
  string(150) "Mental health issues can affect anybody, regardless of their age, personality or workplace – and that includes the rich and famous. British rapp"
  [3]=>
  string(593) "
Mental health issues can affect anybody, regardless of their age, personality or workplace – and that includes the rich and famous. British rapper and mental health support advocate 
&#nl
The post Professor Green and Andrew Flintoff address the key issues with mental health in the workplace appeared first on Compelo -  latest news, features and insight on influencers and innovators within business.
&#nl"
  ["description"]=>
  string(593) "
Mental health issues can affect anybody, regardless of their age, personality or workplace – and that includes the rich and famous. British rapper and mental health support advocate 
&#nl
The post Professor Green and Andrew Flintoff address the key issues with mental health in the workplace appeared first on Compelo -  latest news, features and insight on influencers and innovators within business.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "96"
  ["rss_id"]=>
  string(2) "96"
  [14]=>
  string(55) "https://www.compelo.com/mental-health-in-the-workplace/"
  ["blog_url"]=>
  string(55) "https://www.compelo.com/mental-health-in-the-workplace/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-23 14:25:05"
  ["create_at"]=>
  string(19) "2019-05-23 14:25:05"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "2763"
  ["article_id"]=>
  string(4) "2763"
  [1]=>
  string(25) "Hospitality in HealthCare"
  ["article_title"]=>
  string(25) "Hospitality in HealthCare"
  [2]=>
  string(150) "OverviewHealth care organizations are becoming more competitive and more driven by patient loyalty. Patient loyalty is primarily a function of how a p"
  ["short_description"]=>
  string(150) "OverviewHealth care organizations are becoming more competitive and more driven by patient loyalty. Patient loyalty is primarily a function of how a p"
  [3]=>
  string(516) "OverviewHealth care organizations are becoming more competitive and more driven by patient loyalty. Patient loyalty is primarily a function of how a patient feels they were treated during the receipt of their care. It's more important than ever for medical organizations to remain in-tune with the needs and perceptions of patients as well as providing thorough customer service training to employees. This is what's going to allow medical organizations to gain a competitive edge in a rapidly sh…"
  ["description"]=>
  string(516) "OverviewHealth care organizations are becoming more competitive and more driven by patient loyalty. Patient loyalty is primarily a function of how a patient feels they were treated during the receipt of their care. It's more important than ever for medical organizations to remain in-tune with the needs and perceptions of patients as well as providing thorough customer service training to employees. This is what's going to allow medical organizations to gain a competitive edge in a rapidly sh…"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "3"
  ["category"]=>
  string(1) "3"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "58"
  ["rss_id"]=>
  string(2) "58"
  [14]=>
  string(74) "
https://www.pharmiweb.com/event/hospitality-in-healthcare                "
  ["blog_url"]=>
  string(74) "
https://www.pharmiweb.com/event/hospitality-in-healthcare                "
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-23 14:24:40"
  ["create_at"]=>
  string(19) "2019-05-23 14:24:40"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "2762"
  ["article_id"]=>
  string(4) "2762"
  [1]=>
  string(27) "11th Digital Pharma Europe "
  ["article_title"]=>
  string(27) "11th Digital Pharma Europe "
  [2]=>
  string(150) "The Digital Pharma team and partners at Merck Serono, has made finding the highest-quality keynote sessions and case studies for the 11th Digital Phar"
  ["short_description"]=>
  string(150) "The Digital Pharma team and partners at Merck Serono, has made finding the highest-quality keynote sessions and case studies for the 11th Digital Phar"
  [3]=>
  string(527) "The Digital Pharma team and partners at Merck Serono, has made finding the highest-quality keynote sessions and case studies for the 11th Digital Pharma Europe conference, http://bit.ly/2J9MR6m, their biggest priority. Because of this effort, they've been able to compile a faculty of senior-management-level executives from big pharma and SME life science organisations that continue to innovate and expand their achievements in the digital space.&#nlThey've assembled the most senior, diverse, an…"
  ["description"]=>
  string(527) "The Digital Pharma team and partners at Merck Serono, has made finding the highest-quality keynote sessions and case studies for the 11th Digital Pharma Europe conference, http://bit.ly/2J9MR6m, their biggest priority. Because of this effort, they've been able to compile a faculty of senior-management-level executives from big pharma and SME life science organisations that continue to innovate and expand their achievements in the digital space.&#nlThey've assembled the most senior, diverse, an…"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "3"
  ["category"]=>
  string(1) "3"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "58"
  ["rss_id"]=>
  string(2) "58"
  [14]=>
  string(75) "
https://www.pharmiweb.com/event/11th-digital-pharma-europe                "
  ["blog_url"]=>
  string(75) "
https://www.pharmiweb.com/event/11th-digital-pharma-europe                "
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-23 14:24:40"
  ["create_at"]=>
  string(19) "2019-05-23 14:24:40"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}